Home/Filings/4/0001127602-22-005441
4//SEC Filing

WELTZIEN LOURDES 4

Accession 0001127602-22-005441

CIK 0000794172other

Filed

Feb 16, 7:00 PM ET

Accepted

Feb 17, 11:22 AM ET

Size

12.0 KB

Accession

0001127602-22-005441

Insider Transaction Report

Form 4
Period: 2022-02-15
WELTZIEN LOURDES
EVP, Life Science
Transactions
  • Sale

    Common Stock

    2022-02-15$25.60/sh20,000$511,91283,048 total
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2022-02-1512,5000 total
    Exercise: $14.65Exp: 2027-11-08Common Stock (12,500 underlying)
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2022-02-157,5002,500 total
    Exercise: $14.30Exp: 2028-04-24Common Stock (7,500 underlying)
  • Exercise/Conversion

    Common Stock

    2022-02-15$14.30/sh+7,500$107,250103,048 total
  • Exercise/Conversion

    Common Stock

    2022-02-15$14.65/sh+12,500$183,12595,548 total
Footnotes (3)
  • [F1]The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $25.29 to $26.07. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
  • [F2]These non-qualified options were awarded under the 2012 Stock Incentive Plan and cliff vested in full on November 15, 2021.
  • [F3]These options were awarded under the 2012 Stock Incentive Plan and vest in four equal installments from the date of grant until fully vested on April 24, 2022.

Issuer

MERIDIAN BIOSCIENCE INC

CIK 0000794172

Entity typeother

Related Parties

1
  • filerCIK 0001201184

Filing Metadata

Form type
4
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 11:22 AM ET
Size
12.0 KB